Impax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.18, $0.04 better than the analyst estimate of $0.14. Revenue for the quarter came in at $202.1 million versus the consensus estimate of $195.62 million.

GUIDANCE:

Impax Laboratories sees FY2017 EPS of $0.55-$0.70, versus the consensus of $0.66.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.